| Chesapeake Eye Care & Laser Center Llc | |
|
200 Washington Heights Med Ctr, Westminster, MD 21157-5633 | |
| (410) 848-4095 | |
| Not Available |
| Full Name | Chesapeake Eye Care & Laser Center Llc |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 200 Washington Heights Med Ctr, Westminster, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780235820 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Chesapeake Eye Care & Laser Center Llc 2002 Medical Pkwy Ste 320, Annapolis, MD 21401-7901 Ph: (410) 571-8733 | Chesapeake Eye Care & Laser Center Llc 200 Washington Heights Med Ctr, Westminster, MD 21157-5633 Ph: (410) 848-4095 |
News Archive
Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.
Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.
Researchers at the University of Chicago Medicine and the University of Illinois at Chicago (UIC) are launching an investigational study to determine the effects of increased education and access to rapid, FDA-approved COVID-19 testing on community perceptions, access, and use of COVID-19 testing resources.
Leto Medical, LLC, a privately held, early-stage medical device company, announced today that the United States Patent and Trademark Office has granted the company two patents (7,765,006 and 7,765,007) for its breakthrough Continent Ostomy System technology, a system of products that will restore continence control to individuals with colostomies.
› Verified 2 days ago